IMPL News and Press, Impel Pharmaceuticals Inc. From 03/17/23

SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2...

SEATTLE, March 03, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Company will participate in two upcoming ...

Impel Pharmaceuticals ( NASDAQ: IMPL ) on Wednesday said it would implement cost saving measures including eliminating pipeline programs and reducing its workforce. The company said it would cut its headcount by 16% and would reprioritize its spending on the development of its Trudhes...

Cost-Saving Measures Eliminate Pipeline Programs and Reduce Headcount by 16 Percent Company will Continue to Drive Trudhesa Growth Via 90 Field-Based Sales Representatives and Other Commercial Efforts Trudhesa Growth Momentum Continues, with 58 Percent Increase in New Prescripti...

Wedbush downgraded Impel Pharmaceuticals ( NASDAQ: IMPL ) to Neutral from Outperform on Tuesday, noting uncertain commercial prospects for Trudhesa, an FDA-approved therapy for migraine in adults. The analyst Laura Chico argues that the uptake for Trudhesa continues to lag e...

Impel Pharmaceuticals Inc. (IMPL) Q3 2022 Results Conference Call November 14, 2022 08:30 AM ET Company Participants John Leaman - Chief Financial & Business Officer Adrian Adams - Chairman & CEO Leonard Paolillo - Chief Commercial Officer Conferenc...

Impel NeuroPharma press release ( NASDAQ: IMPL ): Q3 GAAP EPS of -$1.31 misses by $0.32 . Revenue of $3.1M (+244.4% Y/Y) misses by $2.65M . For further details see: Impel NeuroPharma GAAP EPS of -$1.31 misses by $0.32, revenue of $3.1M misses by $2.65M

Trudhesa ® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch Impel to Host Investor Conference Call Today at 8:3...

SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that the Adrian Adams, Chairman and Chief Exe...

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, Novemb...